心脏移植后 PCSK9 抑制剂的安全性和疗效。
Safety and Efficacy of PCSK9 Inhibitors After Heart Transplantation.
机构信息
Stanford University, Division of Cardiovascular Medicine, Heart Transplantation, Palo Alto, California, USA; Ted Rogers Centre of Excellence in Heart Function, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
Ted Rogers Centre of Excellence in Heart Function, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
出版信息
Can J Cardiol. 2019 Jan;35(1):104.e1-104.e3. doi: 10.1016/j.cjca.2018.11.004. Epub 2018 Nov 14.
Dyslipidemia is common in patients undergoing heart transplantation and is associated with the progression of cardiac allograft vasculopathy. Two monoclonal antibodies directed against PCSK9i-evolocumab and alirocumab-are currently available. However, their use, safety and efficacy in the post-transplant setting have not been studied. We present our experience with 6 heart transplant recipients treated with a PCSK9i. A > 70% reduction in LDL-cholesterol was observed after evolocumab therapy. PCSK9 inhibitors are a potentially lipid-lowering therapeutic option for heart transplant patients with suboptimal LDL despite maximal tolerated statin doses.
血脂异常在接受心脏移植的患者中很常见，并且与心脏移植后血管病变的进展有关。目前有两种针对 PCSK9 的单克隆抗体药物——依洛尤单抗和阿利西尤单抗可用。然而，它们在移植后的应用、安全性和疗效尚未得到研究。我们报告了 6 例接受 PCSK9i 治疗的心脏移植受者的经验。依洛尤单抗治疗后 LDL-胆固醇降低了>70%。对于最大耐受他汀剂量后 LDL 仍不理想的心脏移植患者，PCSK9 抑制剂是一种潜在的降脂治疗选择。
Zotero 插件